Zyngenia Inc

Zyngenia Inc. is a privately held biotechnology company headquartered in Washington, DC. With a team of six employees, the company focuses on developing innovative biotherapeutics. Zyngenia specializes in creating a new class of drugs called Zybodies™, which are monoclonal antibody-based therapeutics designed to target multiple physiological pathways simultaneously. This approach aims to more effectively treat complex diseases such as cancer, inflammation, and autoimmune disorders. The company's pipeline includes three programs in preclinical development, with preclinical proof-of-concept achieved for both bi-specific and tri-specific programs in cancer and inflammation. What sets Zyngenia apart is its unique technology platform. Zybodies™ combine the multi-functionality of novel drug designs with the well-established drug-like properties of conventional monoclonal antibodies. This innovative approach allows for the development of highly specific treatments while utilizing standard commercial production processes. For inquiries or partnership opportunities, you can visit Zyngenia's website at zyngenia.com.